RxDoctor Payments Data

Gabriella Gerstle, MD

Neurology · Boynton Beach, FLNPI 1679612055

Payments from drug & device makers

$202,735in general payments, 2019–2025

Across 679 payments — averaging $298.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$141K
  • UCB SA$17K
  • Biogen$11K
  • SK Life Science, Inc.$9K
  • Genentech, Inc.$8K
  • Novartis$5K
  • plus $12K from 49 others

What the payments were for

  • Consulting fees$7,20032%
  • Speaking & faculty fees$2471%
  • Travel & lodging$1,4226%
  • Food & beverage$13,92261%
  • Education$490%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$202,735 in reported general payments places this provider in the 85th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$221,143
Medicare patients
460
Services billed
1,728

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa66$83,600
BriviactBrivaracetam23$33,092
Nurtec OdtRimegepant Sulfate11$21,653
Lamotrigine OdtLamotrigine13$9,770
Memantine Hcl ErMemantine Hcl115$7,733
FycompaPerampanel11$6,478
TegretolCarbamazepine11$4,886
Memantine Hcl225$4,404
Lacosamide28$3,883
Donepezil Hcl482$3,742
Rivastigmine16$3,003
Lidocaine27$2,395
Levetiracetam90$2,298
Gabapentin207$2,297
Pyridostigmine Bromide26$2,135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide, Mycophenolate Mofetil$984$86,508103 claims
UCB, Inc.Briviact$2,065$33,09223 claims
PfizerNurtec Odt$76$21,65311 claims
Eisai Inc.Fycompa$140,590$6,47811 claims
Upsher-smith Laboratories LLCTopiramate$30$51056 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,434 neurology providers in Florida.

Other neurology in Boynton Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →